dc.contributor.author
Scheibe, Franziska
dc.contributor.author
Metz, Imke
dc.contributor.author
Radbruch, Helena
dc.contributor.author
Siebert, Eberhard
dc.contributor.author
Wolf, Stefan
dc.contributor.author
Köhnlein, Martin
dc.contributor.author
Harms, Lutz
dc.contributor.author
Meisel, Andreas
dc.date.accessioned
2019-04-10T07:06:12Z
dc.date.available
2019-04-10T07:06:12Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/24337
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-2109
dc.description.abstract
Currently, 12 cases (including our patient) of autoimmune encephalitis/encephalopathy after daclizumab therapy in MS are known worldwide and led to voluntary withdrawal of marketing authorization for daclizumab by the manufacturer Biogen (press release from European Medicines Agency, 07.03.2018).
Our findings suggest that early recognition of DRESS even with CNS manifestations and swift treatment with steroids and/or plasma exchange are essential to improve the longterm outcome.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
dress syndrome
en
dc.subject
eosinophilia
en
dc.subject
daclizumab therapy
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
e479
dcterms.bibliographicCitation.doi
10.1212/NXI.0000000000000479
dcterms.bibliographicCitation.journaltitle
Neurology: Neuroimmunology & Neuroinflammation
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
Wolters Kluwer
dcterms.bibliographicCitation.volume
5
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
30027105
dcterms.isPartOf.issn
2332-7812
